دورية أكاديمية
Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity.
| العنوان: | Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity. |
|---|---|
| المؤلفون: | Korsholm LM; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Kjeldsen M; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Perino L; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Mariani L; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Nyvang GB; Department of Oncology, Odense University Hospital, Odense, Denmark., Kristensen E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Bagger FO; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Mirza MR; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Rossing M; Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. |
| المصدر: | JCO precision oncology [JCO Precis Oncol] 2024 Feb; Vol. 8, pp. e2300483. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Alexandria, VA : American Society of Clinical Oncology, [2017]- |
| مواضيع طبية MeSH: | Antineoplastic Agents* , Ovarian Neoplasms*/diagnosis , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/genetics, Humans ; Female ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/therapeutic use ; Homologous Recombination/genetics ; Progression-Free Survival ; Rad51 Recombinase/genetics |
| مستخلص: | Purpose: To meet the urgent need for accessible homologous recombination-deficient (HRD) test options, we validated a laboratory-developed test (LDT) and a functional RAD51 assay to assess patients with ovarian cancer and predict the clinical benefit of poly(ADP-ribose) polymerase inhibitor therapy. Methods: Optimization of the LDT cutoff and validation on the basis of samples from 91 patients enrolled in the ENGOT-ov24/NSGO-AVANOVA1&2 trial (ClinicalTrials.gov identifier: NCT02354131), previously subjected to commercial CDx HRD testing (CDx). RAD51 foci analysis was performed and tumors with ≥five foci/nucleus were classified as RAD51-positive (homologous recombination-proficient). Results: The optimal LDT cutoff is 54. Comparing CDx genome instability score and LDT HRD scores show a Spearman's correlation of rho = 0.764 ( P < .0001). Cross-tabulation analysis shows that the sensitivity of the LDT HRD score is 86% and of the LDT HRD status is 91.8% (Fisher's exact test P < .001). Survival analysis on progression-free survival (PFS) of LDT-assessed patients show a Cox regression P < .05. RAD51 assays show a correlation between low RAD51 foci detection (<20% RAD51 + cells) and significantly prolonged PFS ( P < .001). Conclusion: The robust concordance between the open standard LDT and the CDx, especially the correlation with PFS, warrants future validation and implementation of the open standard LDT for HRD testing in diagnostic settings. |
| References: | Ann Oncol. 2018 May 1;29(5):1203-1210. (PMID: 29635390) Cancer Res. 2012 Nov 1;72(21):5588-99. (PMID: 23118055) EMBO Mol Med. 2021 May 7;13(5):e13366. (PMID: 33709473) Ann Oncol. 2022 Oct;33(10):1021-1028. (PMID: 35772665) Nature. 2005 Apr 14;434(7035):917-21. (PMID: 15829967) Expert Rev Mol Diagn. 2022 Feb;22(2):185-199. (PMID: 34913794) Cancer Chemother Pharmacol. 2019 Oct;84(4):791-798. (PMID: 31375879) Nature. 2005 Apr 14;434(7035):913-7. (PMID: 15829966) N Engl J Med. 2012 Apr 12;366(15):1382-92. (PMID: 22452356) N Engl J Med. 2019 Dec 19;381(25):2416-2428. (PMID: 31851799) Mod Pathol. 2023 Mar;36(3):100049. (PMID: 36788098) Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. (PMID: 29858219) NPJ Precis Oncol. 2022 Dec 29;6(1):96. (PMID: 36581696) Lancet Oncol. 2019 Oct;20(10):1409-1419. (PMID: 31474354) Springerplus. 2016 Jul 28;5(1):1197. (PMID: 27516935) Cancers (Basel). 2021 Feb 28;13(5):. (PMID: 33670893) Clin Cancer Res. 2016 Aug 1;22(15):3764-73. (PMID: 26957554) Cancer Res. 2012 Nov 1;72(21):5454-62. (PMID: 22933060) Nature. 2011 Jun 29;474(7353):609-15. (PMID: 21720365) Nat Rev Dis Primers. 2016 Aug 25;2:16061. (PMID: 27558151) Br J Cancer. 2012 Nov 6;107(10):1776-82. (PMID: 23047548) Cancers (Basel). 2021 Jun 15;13(12):. (PMID: 34203855) Cancer Res. 2022 Apr 15;82(8):1646-1657. (PMID: 35425960) Cancer Discov. 2012 Apr;2(4):366-375. (PMID: 22576213) Nat Genet. 2013 Oct;45(10):1113-20. (PMID: 24071849) Clin Cancer Res. 2014 Sep 15;20(18):4816-26. (PMID: 24963051) Oncogene. 2022 Jun;41(26):3498-3506. (PMID: 35662281) EMBO Mol Med. 2018 Dec;10(12):. (PMID: 30377213) Clin Cancer Res. 2023 Aug 15;29(16):3110-3123. (PMID: 36805632) Genes Chromosomes Cancer. 2021 May;60(5):299-302. (PMID: 33486842) N Engl J Med. 2019 Dec 19;381(25):2391-2402. (PMID: 31562799) Gynecol Oncol. 2023 Apr;171:106-113. (PMID: 36868112) J Pharmacol Exp Ther. 2015 Jun;353(3):446-57. (PMID: 25758918) |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02354131 |
| المشرفين على المادة: | 0 (Poly(ADP-ribose) Polymerase Inhibitors) 0 (Antineoplastic Agents) EC 2.7.7.- (RAD51 protein, human) EC 2.7.7.- (Rad51 Recombinase) |
| تواريخ الأحداث: | Date Created: 20240301 Date Completed: 20240304 Latest Revision: 20240309 |
| رمز التحديث: | 20240309 |
| مُعرف محوري في PubMed: | PMC10919475 |
| DOI: | 10.1200/PO.23.00483 |
| PMID: | 38427930 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2473-4284 |
|---|---|
| DOI: | 10.1200/PO.23.00483 |